Total Clarity Wealth Management Inc. increased its position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 59.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,718 shares of the company’s stock after purchasing an additional 3,998 shares during the period. Total Clarity Wealth Management Inc. owned 0.16% of VanEck Pharmaceutical ETF worth $980,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Financial Partners Group Inc bought a new position in VanEck Pharmaceutical ETF in the 2nd quarter worth approximately $8,701,000. J.Safra Asset Management Corp purchased a new position in VanEck Pharmaceutical ETF during the first quarter valued at $6,306,000. Bricktown Capital LLC bought a new stake in VanEck Pharmaceutical ETF in the 2nd quarter valued at $5,904,000. Avestar Capital LLC purchased a new stake in VanEck Pharmaceutical ETF in the 4th quarter worth $4,284,000. Finally, Gladstone Institutional Advisory LLC bought a new position in shares of VanEck Pharmaceutical ETF during the 4th quarter valued at about $3,818,000.
VanEck Pharmaceutical ETF Price Performance
NASDAQ PPH opened at $97.52 on Monday. VanEck Pharmaceutical ETF has a 1-year low of $74.05 and a 1-year high of $99.51. The stock has a market capitalization of $657.28 million, a PE ratio of 21.04 and a beta of 0.72. The business has a 50 day simple moving average of $95.08 and a two-hundred day simple moving average of $91.50.
VanEck Pharmaceutical ETF Cuts Dividend
About VanEck Pharmaceutical ETF
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Further Reading
- Five stocks we like better than VanEck Pharmaceutical ETF
- How to Invest in Insurance Companies: A Guide
- Analysts See 51% Upside in Coinbase, Is It Time to Buy the Hype?
- How Can Investors Benefit From After-Hours Trading
- 3 Defensive Stock Alternatives to Bonds If Interest Rates Drop
- How to Buy Cheap Stocks Step by Step
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.
